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ABSTRACT  
Cilnidipine is one of the dihydropyridine calcium antagonists. It was created combinedly by Fuji Viscera Pharmaceutical Company, Ajinomoto 
and Japan and was approved in the year 1995. Cilnidipine acts on N-type calcium channel where exist the end of sympathetic nerve in addition 
to common L-type calcium channel like that of other calcium antagonists. China, Japan, India, Korea and several other countries approved this 
drug. The objective of the method validation is to demonstrate whether the method was suited for the intended purpose. The method was 
validated as per the ICH guidelines. The method was validated for linearity, precision (repeatability, intermediate precision), accuracy, 
specificity, robustness, limit of detection and limit of quantification. Cosmosil (4.6 X 250mm, 5 μ) column was used for separation. The selected 
wavelength for Cilnidipine was 241 nm. The mobile phase consists Methanol: Potassium dihydrogen phosphate buffer (50:50). Flow rate was 
delivered at 1.0 mL/min. Appropriate dilutions of standard stock solutions were prepared as per the get desired concentrations in the range of 
100-500 mcg/ml. The RT obtained was 4.8165 minutes.  
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INTRODUCTION: 
Cilnidipine is one of the dihydropyridine calcium 
antagonists. It was created combinedly by Fuji Viscera 
Pharmaceutical Company, Ajinomoto and Japan and was 
approved in the year 1995. Cilnidipine acts on N-type 
calcium channel where exist the end of sympathetic nerve in 
addition to common L-type calcium channel like that of other 
calcium antagonists. China, Japan, India, Korea and several 
other countries approved this drug.1 
IUPAC nomenclature: 3-(2-methoxyethyl) 5-(2E)-3-
phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate 
Literature review suggest few RP-HPLC, HPTLC, 
spectroscopic, stability indicating HPLC determinations were 
performed.2-15 The aim of the present study is to develop a 
simple, precise, accurate, sensitive HPLC method for the 
determination. After, doing in depth study in the present 
research work, it was found that the present research work 
is having various advantages over the previous work. The 
advantages include less retention times of the component, 
with good resolution. The % RSD of robustness was found to 
be less. The results obtained from the validation suggest that 
the method was found to be precise, accurate, linear and 
robust enough and the method was also found to be 
economical.  
  
Figure 1: Structure of Cilnidipine 
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EXPERIMENTAL WORK: 
Chemicals and reagents: HPLC grade acetonitrile, 
methanol, from Spectro Chemie. Ammonium acetate, acetic 
acid of analytical grade was used. Millipore grade water was 
used. The reference standard samples of Cilnidipine was 
provided was provided by Ajanta Pharma.  
Instrumentation and analytical conditions:  
The analysis was carried out by using Younglin (S.K) 
Gradient System UV Detector, 4.6X250mm cosmosil column, 
20ml loop size HPLC (With UV/Vis Detector. Other 
instrumentation includes Double beam UV- Visible 
spectrophotometer Simadzu UV-1800, digital balance 
(metler tolado), vacuum pump (Gelman science), pH meter 
(poloman). 
Chromatographic conditions: 
Cosmosil (4.6X250mm, 5 μ) column was used for separation. 
Methanol: Potassium dihydrogen phosphate buffer (50:50) 
was the optimized mobile phase. 
Preparation of Standard stock solution:  
100 mg of Cilnidipine was weighed in to 100 ml volumetric 
flasks. The drug was dissolved in 40 ml of solvent, and 
shaken manually for 10 min. The volume was made up to the 
mark with solvent and the final strength obtained was 1000 
µg/ml.  
Preparation of Working Standard Solutions: 
10ml of the standard stock solution of Cilnidipine was 
pipette out in to 100 ml volumetric flasks and the volume 
was made up to the mark with solvent, and the final strength 
obtained was 100µg/ml.  
Validation procedure: 
Method validation has the objective of establishing the 
suitability of any method for the experimental purposes. 
Method validation are carried out as per the ICH guidelines. 
Linearity, precision (repeatability, intermediate precision), 
accuracy, specificity, robustness, limit of detection and limit 
of quantification were checked in the method validation. A 
calibration curve was constructed by taking six different 
concentrations. The peak area was calculated, and 
calibration curve was constructed by taking peak area and 
concentration on both the axis. The linearity was evaluated 
by linear regression analysis. The precision studies were 
demonstrated by two parameters inter day and intraday 
precision. Intraday precision was performed by injecting six 
replicated injections to the chromatographic system on the 
same day and calculated the %RSD. The inter day precision 
was performed by injecting six replicated injections at two 
consecutive days. From the peak area of the chromatograms, 
the %RSD was calculated. The accuracy was determined by 
adding a known amount of the standard to the sample, and 
the percentage recovery was estimated. The robustness was 
determined by incorporating deliberate changes into the 
method conditions like the change in flow rate, pH, and 
gradient.  
RESULTS AND DISCUSSION:  
Selection of wavelength:  
UV spectrum was obtained by preparing a solution by taking 
diluents and scanned between 200 to 400 nm. Brinzolamide 
shows λmax at 241 nm. So, it is selected as a detection 
wavelength. 
 
Figure 2: Spectrum of Cilnidipine 
Standard curve of Cilnidipine: 
 
Figure 3: Standard curve of Cilnidipine 
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Development and optimization of the HPLC method:  
For getting an optimized chromatographic condition, A 
Cosmosil (4.6X250mm, 5 μ) column was used for separation. 
The mobile phase consists of Methanol: Potassium 
dihydrogen phosphate buffer (50:50). Flow rate was 
delivered at 1.0 mL/min with detection wavelength at 241 
nm.  20 μL was injected to the chromatographic system with 
ambient temperature. The RT obtained was 4.8165 minutes.
 
 
Figure 4: RT of Brinzolamide 
Method validation: 
 Linearity:  
Appropriate dilutions of standard stock solutions were prepared to get desired concentrations in the range of 100-500 mcg/ml. 
Then the concentrations were plotted against the area under curves to get the equation of standard curve, as presented in Table 
1.  
Table 1: Dilutions for linearity study 
Stock solution (µl) Diluted (ml) Final concentration 
100 10 10 
200 10 20 
300 10 30 
400 10 40 
500 10 50 
 
Table 2: Linearity Data 
Sr. No. Conc. in (µg/ml) Mean AUC (n = 5) %RSD 
1 10 4198 0.567 
2 20 8813 0.493 
3 30 12412 0.681 
4 40 17289 0.392 
5 50 21432 0.764 
Precision: 
Precision is determined at two levels: a) Repeatbility b) Intraday and Interday Precision. 
Table 3: Precision Data 
Parameter Amount taken (µg/ml) Amount found* (µg/ml) %RSD 
System Precision 60 59.91 0.681 
Method Precision 60 60.12 0.592 
*Mean of Six observations 
Table 4: Intraday  and Interday Precision Data 
Concentration of Brinzolamide Intraday* %RSD Interday * %RSD 
20µg/ml 20.09 0.118 19.92 0.249 
40µg/ml 39.92 0.132 39.94 0.362 
60 µg/ml 60.13 0.209 59.91 0.419 
*Mean of three observations 
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Accuracy: 
To check the accuracy of the developed methods, analytical 
recovery experiment was carried out by standard addition 
method. Recovery study was performed by adding 80, 100 
and 120 % of the test concentration as per ICH guidelines. 
Table 5: Accuracy 
Sr. 
No. 
Concentration 
of Drug Added 
(µg/ml) 
Concentration 
of Drug Added 
(µg/ml) 
%    Recovery±  
SD 
1 64 10.4 99.99  ± 0.182 
2 80 13 99.82  ± 0.273 
3 96 15.6 98.77  ±0.317 
 
Limit of Quantification (LOQ) and Limit of Detection 
(LOD):  
The limit of quantification (LOQ) is defined as the lower 
concentration of an analyte in a sample that can be 
determined with acceptable precision and accuracy under 
the stated operational conditions of the method. The limit of 
detection (LOD) is defined as the lowest concentration of an 
analyte in a sample that can be detected, not quantified. The 
LOD and LOQ were estimated from the set of 5 calibration 
curves used to determine method linearity. The LOD and 
LOQ were calculated using formula given below. 
LOD = 3.3× σ/S 
LOQ= 10× σ/S 
Where, σ = Standard deviation of the Y- intercepts of the 5 
calibration curves, S = Mean slope of the 5 calibration curves. 
The LOQ and LOD parameters of Brinzolamide are provided 
in Table 6. 
Table 6: LOD and LOQ parameters 
Parameter Values 
S.D. of Intercept* 0.6148 
Mean Slope of Calibration Curve* 430.79 
LOD (μg/ml) 0.00471 
LOQ (μg/ml) 0.01427 
 
Robustness: 
Robustness was studied by observing the change in 
following parameters, and then observation of each 
parameter change was done to access their effect on system 
suitability and assay. Change in mobile phase composition 
was done by ± 5.0 ml of organic solvent and the change in 
the detection wavelength ± 10 nm was done. 
Change in mobile phase composition: The sample solution 
at test concentration (60μg/ml of drug was injected thrice 
with the mobile phase composition changed by ± 5.0ml of 
organic solvent from the developed method.  
Change in detection wavelength: The sample solution at 
test concentration (60μg/ml of drug was injected thrice with 
the change in detection wavelength by ± 10 nm from the 
developed method. The % assay of drug after changes in 
method parameters were observed. 
CONCLUSION: 
A precise RP – HPLC method was developed for the 
determination of Brinzolamide. The shorter run time elutes 
Erlotinib hydrochloride with good resolution, and 
symmetry. The method was validated as per the ICH 
guidelines and the method was found to be simple, precise, 
linear, accurate, rugged and robust enough. 
Table 7: Summary of Validation parameters 
Parameters Cilnidipine 
Accuracy  98.77 ±0.317– 99.99 ± 0.182 
Precision (%RSD) 
System Precision 0.681 
Method Precision 0.592 
Intra-day (n = 3) 0.118 - 0.209 
Inter-day (n = 3) 0.249 - 0.419 
LOD and LOQ 
LOD 0.00471 
LOQ 0.01427 
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